PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Opportunities for Bioinformatics in European Drug Discovery Market - Frost & Sullivan finds that the European Bioinformatics Market earned revenues of $392 million in 2006 and estimates to grow to $955.2 million in 2013
Opportunities for Bioinformatics in European Drug Discovery Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/06/20 - Frost & Sullivan finds that the European Bioinformatics Market earned revenues of $392 million in 2006 and estimates to grow to $955.2 million in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The European bioinformatics industry is competing in a growing market, which is dominated by a few large vendors. Bioinformatics has varied applications in the drug discovery market, including proteomic, genomic and information manipulation applications. Most of the life sciences organisations involved in the process of drug discovery adopt bioinformatics in varying degrees in their routine process. Accordingly, the growth rates in the bioinformatics market are modest yet steady.

Frost & Sullivan (healthcare.frost.com) finds that the European Bioinformatics Market earned revenues of $392 million in 2006 and estimates to grow to $955.2 million in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of Opportunities for Bioinformatics in European Drug Discovery Market, send an email to Radhika Menon Theodore - Corporate Communications at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information through email upon receipt of the above information.

“The large amount of data generated in the process of drug discovery is creating greater demand for improved data handling tools,” notes Frost & Sullivan Research Analyst Mr. Vinod S.M. “It is impossible for professionals to handle and analyse data without the use of advanced computational tools.”

Bioinformatics has been able to constantly develop new tools that are capable of handling high-end voluminous data, thereby facilitating the work of life sciences professionals. Moreover, given the reducing drug pipelines in the European pharmaceutical industry, companies are looking for tools to increase drug research productivity. This demand from pharmaceutical and life sciences companies is another factor influencing the bioinformatics market favourably.

A key factor restraining market growth is the resistance of European companies in adopting new technologies. “Undoubtedly, bioinformatics offers the best forms of application to life sciences companies for the simplification of the drug discovery process,” explains Mr. Vinod. “However, the conservative attitude of European companies is affecting market growth.”

Apart from this, as various companies use different data formats, proprietary and incompatible data formats limit the value of bioinformatics. Moreover, the tools presently used in the European bioinformatics industry mostly serve specialised end users. As these tools require a technical skill set, researches who are directly involved in the R&D process do not get to use the bioinformatics tools.

As a result, all professionals utilising the tools need periodical training on the functioning of the tools to enable them to take full advantage of the functionality. Thus, continuous training and support for life sciences professionals will help drive market growth.

Market participants should also look to acquire or form alliances with companies that can help them broaden their product portfolio, rather than increase their market share. By expanding their product portfolio, smaller companies can hope to actively compete with larger multi-modality vendors.

Opportunities for Bioinformatics in European Drug Discovery Market is part of the Healthcare and Life Sciences IT Subscription, which also includes research in the following markets: genomics, proteomics and information manipulation. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Opportunities for Bioinformatics in European Drug Discovery Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
+91 44 42044541 rmtheodore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)